Clinical observation of fire needle combined with halometasone cream in the treatment of acral vitiligo
- Conditions
- Vitiligo
- Registration Number
- ITMCTR2100004789
- Lead Sponsor
- Dermatology Hospital,Southern Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria and consensus on diagnosis and treatment, meet the criteria for acral typing, meet the criteria for stable stage staging, and be stable for at least 6 months;
2. Aged 18 to 60 years, gender is not limited, the course of disease is less than 5 years;
3. There is no pigment island and self-healing tendency in leukoplakia;
4. The skin lesion area accounts for <= 1% of the body surface area;
5. Have not received immunosuppressive agents, glucocorticoids, non-steroidal anti-inflammatory drugs and other systemic treatments within 3 months, and have not received local treatments within 1 month;
6. Patients who agree to and abide by the diagnosis and treatment plan, voluntarily sign an informed consent form, and cooperate in taking photos before and after treatment.
1. Fainted needles, scarred physique, or extremely fearful of fire needles;
2. Patients who are allergic to halometasone cream;
3. Patients with combined serious diseases, such as serious heart, brain, liver, kidney, hematopoietic system and other system diseases, or patients with malignant tumors;
4. Female patients who are pregnant, breastfeeding or planning to become pregnant within six months;
5. Partial skin lesions have redness, swelling, damage or infection.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method